Revealing the potential of intranasally administered orexin A (hypocretin-1).
Hallschmid
Manfred
M
Department of Neuroendocrinology, University of Lübeck, Lübeck, Germany. hallsch-mid@kfg.uni-luebeck.de
Born
Jan
J
D000281:Administration, Intranasal; D000818:Animals; D004333:Drug Administration Routes; D000882:Haplorhini; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D008568:Memory / Q000187:drug effects; D051379:Mice; D009474:Neurons / Q000187:drug effects; D009479:Neuropeptides / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D000068797:Orexins; D012892:Sleep Deprivation / Q000188:drug therapy
C000596229:HCRT protein, human; D047908:Intracellular Signaling Peptides and Proteins; D009479:Neuropeptides; D000068797:Orexins